2. Signaling Pathways
  3. Immunology/Inflammation
  4. Toll-like Receptor (TLR)
  5. Toll-like Receptor (TLR) Isoform
  6. Toll-like Receptor (TLR) Agonist

Toll-like Receptor (TLR) Agonist

Toll-like Receptor (TLR) Agonists (110):

Cat. No. Product Name Effect Purity
  • HY-W250113
    Zymosan A
    		Agonist
    Zymosan A (Zymosan A from Saccharomyces cerevisiae) is a TLR2 agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury.
  • HY-147295
    Odetiglucan
    		Agonist
    Odetiglucan is a novel β-glucan that is a potent immunostimulant and a Dectin-1 (CLEC7A) agonist. Odetiglucan activates innate immune effector cells and triggers a coordinated anti-cancer immune response.
  • HY-P1181A
    Pam2CSK4 TFA
    		Agonist 99.46%
    Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis.
  • HY-150750A
    ODN M362 sodium
    		Agonist
    ODN M362 sodium is a TLR9 agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of TLR9/TLR6, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer.
  • HY-107202GL
    Polyinosinic-polycytidylic acid (GMP Like)
    		Agonist
    Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
  • HY-125390
    SM-360320
    		Agonist 99.41%
    SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response. SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity.
  • HY-N6612R
    D-Glucuronic acid (Standard)
    		Agonist
    D-Glucuronic acid (Standard) is the analytical standard of D-Glucuronic acid. This product is intended for research and analytical applications. D-Glucuronic acid is a major component of many anti-inflammatory proteoglycans, which can promote embryonic development and inhibit cell aggregation. After being metabolized into ethyl glucuronide (HY-113093), D-Glucuronic acid activates Toll-like receptor 4 (TLR4), causing pain. D-Glucuronic acid and its derivative glucurono-lactone can serve as liver detoxifiers for human health prevention, and its derivatives also possess anti-tumor activity.
  • HY-150743B
    FITC-labeled ODN 2395 sodium
    		Agonist 98.89%
    FITC-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a TLR9 agonist. FITC-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.
  • HY-150724B
    FITC-labeled ODN 1018 sodium
    		Agonist 98.71%
    FITC-labeled ODN 1018 (sodium),an oligodeoxynucleotide, is a TLR-9 agonist. FITC-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.
  • HY-W782032
    3D-Monophosphoryl Lipid A-5
    		Agonist 99.60%
    3D-Monophosphoryl Lipid A-5 (3D-MPLA-5) is a TLR agonist that serves as a vaccine adjuvant and enhances the immunogenicity of vaccines.
  • HY-148338
    TLR8 agonist 5
    		Agonist 98.38%
    TLR8 agonist 5 is a potent TLR8 agonist with an EC50 value of 20 nM for HEK-Blue hTLR8. TLR8 agonist 5 activates the immune response.
  • HY-150741B
    FITC-labeled ODN 2216 sodium
    		Agonist
    FITC-labeled ODN 2216 (sodium) is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. FITC-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.
  • HY-103039
    TLR7 agonist 2
    		Agonist 98.80%
    TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.
  • HY-160715
    BNT411
    		Agonist 99.01%
    BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC).
  • HY-145592
    Ruzotolimod
    		Agonist 99.92%
    Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2.
  • HY-150734
    ODN 2007
    		Agonist
    ODN 2007, a class B CpG ODN (oligodeoxynucleotide), is a Toll-like receptor (TLR) ligand. ODN 2007 can be used as an immunomodulator, vaccine adjuvant, and enhance immune responses in mammals, fish, and humans. ODN 2007 sequence: 5'-TCGTCGTTGTCGTTTTGTCGTT-3'.
  • HY-123291
    SM-276001
    		Agonist 99.70%
    SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer.
  • HY-111792
    GSK1795091
    		Agonist
    GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. Not only, GSK1795091 inhibits tumor growth and increases the survival in mice model, but results in long term survival in influenza challenge model in mice.
  • HY-147310
    CU-CPD107
    		Agonist 98.07%
    CU-CPD107 is a potent, selective toll-like receptor 8 (TLR 8) agonist. CU-CPD107 inhibits TLR8 signaling. CU-CPD107 converts to synergistic agonist activities in the presence of ssRNA and induces TLR8 signaling. CU-CPD107 inhibits proinflammatory factor expression and avoids immune responses in the presence of ssRNA.
  • HY-146245B
    FITC-labeled ODN 1826 sodium
    		Agonist
    FITC-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. FITC-labeled ODN 1826 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.